Pharminox, a Nottingham, UK-based cancer drug discovery and development company, has completed a £1.5m round of equity funding.
Investors include new and existing shareholders.
The company intends to use the funds to progress its portfolio of novel cancer therapeutics.
Led by CEO Peter Worrall, Pharminox is focused on the discovery and development of small molecules targeting DNA damage and inhibition of DNA damage repair mechanisms.
Its lead programme – PMX 500 – aims to identify small molecules that promote rapid cell death of cancer cells.
Formed in 2002 as a spin-out from Oxford University, Pharminox is based at the BioCity facility in Nottingham, UK and is backed by IP Group plc, IP Venture Fund, Oxford University and a number of private investors, management and employees.